NCT00113204View on ClinicalTrials.gov

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

IPI-504

Trial Locations (4)

10011

St. Vincent's Comprehensive Cancer Center, New York

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

02115

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center The David Jurist Research Center, Hackensack

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY